About Us

Targeting Kidney Diseases

S1P Therapeutics is a preclinical-stage biotechnology company focused on developing drugs for the treatment of kidney and autoimmune diseases. Our strategy will realize medicines that are effective with less toxicity than existing S1P pathway drugs.

Vision

Prevent and treat kidney diseases

Vision

Prevent and treat kidney diseases

MISSION
Develop drugs targeting novel nodes in the S1P pathway

About Us

Targeting Kidney Diseases

S1P Therapeutics is a preclinical-stage biotechnology company focused on developing drugs for the treatment of kidney and autoimmune diseases. Our strategy will realize medicines that are effective with less toxicity than existing S1P pathway drugs.

Vision

Prevent and treat kidney diseases

Vision

Prevent and treat kidney diseases

MISSION
Develop drugs targeting novel nodes in the S1P pathway

About Us

Targeting Kidney Diseases

S1P Therapeutics is a preclinical-stage biotechnology company focused on developing drugs for the treatment of kidney and autoimmune diseases. Our strategy will realize medicines that are effective with less toxicity than existing S1P pathway drugs.

Vision

Prevent and treat kidney diseases

Vision

Prevent and treat kidney diseases

MISSION
Develop drugs targeting novel nodes in the S1P pathway

About Us

Targeting Kidney Diseases

S1P Therapeutics is a preclinical-stage biotechnology company focused on developing drugs for the treatment of kidney and autoimmune diseases. Our strategy will realize medicines that are effective with less toxicity than existing S1P pathway drugs.

Vision

Prevent and treat kidney diseases

Vision

Prevent and treat kidney diseases

MISSION
Develop drugs targeting novel nodes in the S1P pathway

About Us

Targeting Kidney Diseases

S1P Therapeutics is a preclinical-stage biotechnology company focused on developing drugs for the treatment of kidney and autoimmune diseases. Our strategy will realize medicines that are effective with less toxicity than existing S1P pathway drugs.

Vision

Prevent and treat kidney diseases

Vision

Prevent and treat kidney diseases

MISSION
Develop drugs targeting novel nodes in the S1P pathway

Management Team

S1P Therapeutics is led by drug hunters and industry leaders with decades of experience in discovery, development, and pharmaceutical startups.

Ron Sayco, CFA/CPA

Chief Executive Officer

Kevin R. Lynch, PhD

Chief Scientific Officer

Webster Santos, PhD

Vice President & Head of Medicinal Chemistry

Best-in-Class Biotech Company

We have developed potent and selective S1P transport inhibitors that are orally bioavailable and suitable for once-a-day dosing with an excellent safety profile.

Biotech website design
Linkedin-in

Ron Sayco, CFA/CPA

Chief Executive Officer

Ron Sayco is Chief Executive Officer at S1P Therapeutics. He received a BS degree from McIntire School of Commerce at the University of Virginia and an MBA from Stanford Graduate School of Business. Ron is a CFA Charterholder and CPA. He has worked in executive management, strategy, and finance roles for high growth businesses from startups to billion-dollar global enterprises. He has participated in over $3B in equity and debt financings and executed over $5B in M&A transactions. He is a Board Member of Checkup & Choices, a digital health platform focused on substance abuse and was formerly CFO of Merlin Cyber, a provider of cybersecurity solutions to the government. Prior to Merlin, Ron was CFO of OverHorizon, a satellite services company and a Board Member of 901D, a portfolio company of Graycliff Partners. Before Merlin, Ron held senior Strategy & Corporate Development roles for France-based Thales Group and UK-based BAE Systems.

Linkedin-in

Kevin R. Lynch, PhD

Chief Scientific Officer

Kevin Lynch is Chief Scientific Officer at S1P Therapeutics. He received a BS degree from Penn State, earned his PhD from the University of Rhode Island and did a postdoc at Columbia University as a Ruth Kirschtein NIH trainee. He is currently Professor and Vice Chair of Pharmacology at the University of Virginia School of Medicine. Prof. Lynch has published more than 180 papers, is an inventor of over 35 issued and pending patents. He was named Inventor of the Year (2010) by UVA’s Patent Foundation, has consulted for several pharmaceutical companies, has advised law firms engaged in patent litigation and has served on numerous NIH grant review panels. Prof. Lynch is an expert pharmacologist who has extensive experience in discovering new drugs targeting proteins in the sphingosine 1-phosphate pathway.

Linkedin-in

Webster Santos, PhD

Vice President and Head of Medicinal Chemistry

Webster Santos is Vice President and Head of Medicinal Chemistry at S1P Therapeutics. He received his BS and PhD from the University of Virginia and trained at Harvard University as a Ruth Kirschtein NIH fellow. He is currently a Professor of Chemistry and Director of the Virginia Tech Center for Drug discovery. He has published over 120 papers, an inventor of over 20 issued and pending patents, and a co-founder of three biotech startup companies. He serves as a standing member of SBCB/CBP NIH study section and on the editorial board of Medicinal Research Reviews, Current Topics in Medicinal Chemistry and Molecules. He is a fellow of the Royal Society of Chemistry, received the Fralin-ICTAS Innovators award, American Chemical Society Young Investigator Award, Chemical Communications and Molecular Biosystems Emerging Investigator, and named as the Blackwood Junior Faculty Fellow of Life Sciences and A.C. Lilly Faculty Fellow of Drug Discovery at Virginia Tech. Dr. Santos is an expert medicinal chemist who has extensive experience in developing novel drugs targeting proteins in the sphingosine-1-phosphate pathway.